Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-sensitive Ovarian Cancer”

219 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 219 results

Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Early research (Phase 1)Ended earlyNCT04907968
What this trial is testing

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer

Who this might be right for
Platinum-sensitive Ovarian Cancer (UPGRADE-A)
Mersana Therapeutics 31
Testing effectiveness (Phase 2)Ended earlyNCT00929162
What this trial is testing

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

Who this might be right for
Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
AstraZeneca 120
Large-scale testing (Phase 3)WithdrawnNCT03632798
What this trial is testing

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
Cordgenics, LLC
Testing effectiveness (Phase 2)Study completedNCT00317772
What this trial is testing

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPeritoneal NeoplasmsFallopian Tube Cancer
M.D. Anderson Cancer Center 19
Early research (Phase 1)UnknownNCT01387399
What this trial is testing

Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
University Hospital, Bonn 9
Early research (Phase 1)Study completedNCT02020707
What this trial is testing

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Who this might be right for
Cervical AdenocarcinomaCervical AdenosarcomaCervical Adenosquamous Carcinoma+45 more
Mayo Clinic 43
Testing effectiveness (Phase 2)Ended earlyNCT00910000
What this trial is testing

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Dana-Farber Cancer Institute 15
Testing effectiveness (Phase 2)Study completedNCT00780039
What this trial is testing

Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Who this might be right for
Ovarian Neoplasms
Merck Sharp & Dohme LLC 58
Testing effectiveness (Phase 2)UnknownNCT01388621
What this trial is testing

Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
WiSP Wissenschaftlicher Service Pharma GmbH 140
Testing effectiveness (Phase 2)Study completedNCT00267696
What this trial is testing

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Ohio State University Comprehensive Cancer Center 45
Early research (Phase 1)Study completedNCT00692900
What this trial is testing

Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
University of Pittsburgh 25
Testing effectiveness (Phase 2)Study completedNCT01941316
What this trial is testing

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Who this might be right for
Small Cell Lung CarcinomaNon Small Cell Lung CarcinomaIrinotecan Sensitive Cancers
Cancer Research and Biostatistics Clinical Trials Consortium 78
Early research (Phase 1)Study completedNCT01995188
What this trial is testing

Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Genentech, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT01705158
What this trial is testing

Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum

Who this might be right for
Ovarian Cancer
ARCAGY/ GINECO GROUP 87
Testing effectiveness (Phase 2)Study completedNCT02584465
What this trial is testing

REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

Who this might be right for
Ovarian Carcinoma
ARCAGY/ GINECO GROUP 68
Early research (Phase 1)Study completedNCT00473954
What this trial is testing

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
EGEN, Inc. 13
Testing effectiveness (Phase 2)Looking for participantsNCT04519151
What this trial is testing

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsCarcinoma, Ovarian EpithelialNeoplasm of Stomach+5 more
Sheba Medical Center 24
Testing effectiveness (Phase 2)Study completedNCT01663857
What this trial is testing

A Study LY2228820 for Recurrent Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Eli Lilly and Company 118
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339553
What this trial is testing

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

Who this might be right for
OvariancancerPlatinum-sensitive Recurrent
Peking University Third Hospital 30
Load More Results